立方制药(003020) - 立方制药调研活动信息(2)

Group 1: Product Development and Market Position - The company anticipates that the sustained-release nifedipine tablets may be included in the seventh batch of national centralized procurement, while other products are not yet eligible for centralized procurement [1] - The Yiqi Hewei capsules, developed by Jiangsu Provincial Hospital, saw a year-on-year sales growth of 137.98% in 2020 and maintained a good growth trend in 2021 [1] - The company has developed its own laser perforation equipment for the preparation of permeation pump formulations, in addition to purchasing domestic and imported equipment [1] Group 2: New Product Pipeline - The company has obtained approval for several new products in 2021, including sustained-release tramadol hydrochloride tablets, sustained-release nifedipine tablets, and raw materials for methylphenidate hydrochloride [2] - The company is planning to continue investing in innovative drugs for controlled-release formulations and ophthalmic medications based on its existing product lines [2] - The company has received 13 approvals for ophthalmic products in 2021 and is also initiating new projects based on existing products [2] Group 3: Competitive Advantage - The company is recognized for its industrialization capabilities in complex formulations, currently having four products on the market, including sustained-release nifedipine tablets and sustained-release doxazosin mesylate tablets [2] - There are five products in the registration review stage, including sustained-release venlafaxine tablets [2] - The company aims to strengthen its core competitiveness by further industrializing complex controlled-release formulations and integrating them with narcotic drugs [2]